ArticleFrontiers in cellular and infection microbiology2026
A multi-centre study on cervical cancer screening reveals population-related impact on cervical intraepithelial neoplasia rate.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To conduct a three-year cervical cancer screen in Zhejiang, Sichuan, Beijing, and Inner Mongolia and analyse clinical and population data to identify possible improvements to the screening protocol. Methods: A standard protocol including human papillomavirus (HPV) detection, cytology test, colposcopy, and histopathology inspection was adapted for the screening. Additional HPV genotyping was performed for participants in Sichuan, Beijing, and Inner Mongolia. Results: 12,086 women were included in this study, and 178 cases of cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN2+) were identified. Detailed analyses on features of age, region, ethnicity, and origin showed a notable correlation between age strata and high-grade CIN rates. Moreover, apart from HPV16/18, other HPV types such as HPV33, HPV52, and HPV58 were found to be enriched in high-grade CIN cases, as was repeat positivity. Conclusions: Our results suggest that age, HPV16, and ThinPrep cytologic test (TCT) are prominent exploratory predictors for CIN2+ detection, and HPV33, 52, and 58 may pose higher risks than other non-HPV16/18 types. Future studies incorporating prospective effectiveness and health-economic evaluation are required to validate the clinical utility of these predictors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.